1. Scrip
  2. >>Business

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA
Overall profile for Amgen's MariTide in obesity gets mixed reviews • Source: Shutterstock

Amgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II trial and a Phase I pharmacokinetic study, it knows the right approach in Phase III to improve the bispecific GLP-1 agonist/GIP receptor antagonist antibody’s gastrointestinal tolerability without sacrificing efficacy.

Key Takeaways
  • Amgen updated the field on its Phase II bispecific antibody for obesity, showing 52-week data that analysts called competitive but with troubling tolerability findings.

The just-concluded American Diabetes Association annual meeting provided a platform for several obesity updates. Eli Lilly won the biggest plaudits...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Therapy Areas

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.